Advanced search
Publication Cover
Clinical and Experimental Gastroenterology Volume 13, 2020 - Issue
Submit an article Journal homepage
137
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis

Katsuaki Ogushi1 Gastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-7968-8933
ORCID Icon,
Makoto Chuma1 Gastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0963-9172
ORCID Icon,
Haruki Uojima2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Hisashi Hidaka2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, JapanORCID Iconhttps://orcid.org/0000-0002-4151-5663
ORCID Icon,
Kazushi Numata1 Gastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0003-4671-4431
ORCID Icon,
Satoshi Kobayashi3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Shunji Hirose4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
,
Nobuhiro Hattori5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
,
Tomoaki Fujikawa6 Department of Gastroenterology, Shonan Fujisawa General Hospital, Fujisawa, Japan
,
Takahide Nakazawa2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Naohisa Wada2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Shuitirou Iwasaki2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Taito Fukushima3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Yusuke Sano3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-7753-8712
ORCID Icon,
Makoto Ueno3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0003-4480-0029
ORCID Icon,
Kuniyuki Kawano3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Kota Tsuruya4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, JapanORCID Iconhttps://orcid.org/0000-0002-9884-8039
ORCID Icon,
Masako Shomura4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
,
Tsunamasa Watanabe5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
,
Kotaro Matsunaga5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
,
Yosuke Kunishi7 Department of Gastroenterology, Kanagawa Prefectural Ashigarakami Hospital, Kanagawa, Japan
,
Yusuke Saigusa8 Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0003-4785-7653
ORCID Icon,
Kuniyasu Irie9 Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan
,
Shogo Iwabuchi6 Department of Gastroenterology, Shonan Fujisawa General Hospital, Fujisawa, Japan
,
Makoto Kako10 Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura, Japan
,
Manabu Morimoto3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Tatehiro Kagawa4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
,
Katsuaki Tanaka11 Gastroenterology Division, Hadano Red Cross Hospital, Hadano, Japan
&
Shin Maeda9 Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan
 show all
Pages 385-396 | Published online: 01 Oct 2020

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Mara Persano, Andrea Casadei-Gardini, Valentina Burgio, Mario Scartozzi, Stefano Cascinu & Margherita Rimini. (2023) Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?. Expert Review of Anticancer Therapy 23:1, pages 19-27.
Read now
Bowen Chen, Linzhi Zhang, Jiamin Cheng, Tong Wu, Jin Lei, Xu Yang, Rongling Zhang, Rifaat Safadi, Yinyin Li, Tongguo Si & Yinying Lu. (2022) Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. Drug Design, Development and Therapy 16, pages 4429-4437.
Read now
Angelo Dipasquale, Arianna Marinello & Armando Santoro. (2021) A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario. Journal of Hepatocellular Carcinoma 8, pages 241-251.
Read now
Martina Catalano, Andrea Casadei-Gardini, Gianmarco Vannini, Claudia Campani, Fabio Marra, Enrico Mini & Giandomenico Roviello. (2021) Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Review of Clinical Pharmacology 14:11, pages 1353-1365.
Read now

Articles from other publishers (19)

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu & Andrea Casadei-Gardini. (2022) Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. Journal of Cancer Research and Clinical Oncology 149:9, pages 5591-5602.
Crossref
Ismael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena, Sergio Muñoz-Martínez, Ezequiel Mauro, Neus Llarch, Gemma Iserte, Alejandro Forner, José Rios, Jordi Bruix & María Reig. (2023) Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology 77:4, pages 1139-1149.
Crossref
Maria Tampaki, George V. Papatheodoridis & Evangelos Cholongitas. (2023) Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. Cancers 15:4, pages 1310.
Crossref
Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Katsuaki Motoyoshi & Masatoshi Kudo. (2023) Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan. Drugs - Real World Outcomes.
Crossref
Michio Kimura, Hiroki Asano, Eiseki Usami, Hitomi Teramachi & Tomoaki Yoshimura. (2022) Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, pages 107815522211454.
Crossref
Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alexander Philipp, Thomas Berg, Heinz J. Klümpen, Julia Benckert, Maciej Pech, Antonio Gasbarrini, Holger Amthauer, Peter Bartenstein, Bruno Sangro, Peter Malfertheiner, Jens Ricke & Max Seidensticker. (2022) Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. European Journal of Nuclear Medicine and Molecular Imaging 49:13, pages 4716-4726.
Crossref
Kurvi Patwala, David Stephen Prince, Yael Celermajer, Waafiqa Alam, Eldho Paul, Simone Irene Strasser, Geoffrey William McCaughan, Paul Gow, Siddharth Sood, Elise Murphy, Stuart Roberts, Elliot Freeman, Elizabeth Stratton, Scott Anthony Davison, Miriam Tania Levy, McCawley Clark-Dickson, Vi Nguyen, Sally Bell, Amanda Nicoll, Ashley Bloom, Alice Unah Lee, Marno Ryan, Jessica Howell, Zina Valaydon, Alexandra Mack, Ken Liu & Anouk Dev. (2022) Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study. Hepatology International 16:5, pages 1170-1178.
Crossref
Carla Pires Amaro, Michael J. Allen, Jennifer J. Knox, Erica S. Tsang, Howard J. Lim, Richard M. Lee‐Ying, Kelvin W. Chan, Jessica Qian, Brandon M. Meyers, Alia Thawer, Sulaiman M. S. Al‐Saadi, Tina Hsu, Ravi Ramjeesingh, Hatim Karachiwala, Tasnima Abedin & Vincent C. Tam. (2022) Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian database. Liver Cancer International 3:3, pages 119-127.
Crossref
Yutaka Yasui, Masayuki Kurosaki, Kaoru Tsuchiya, Yuka Hayakawa, Chitomi Hasebe, Masami Abe, Chikara Ogawa, Kouji Joko, Hironori Ochi, Toshifumi Tada, Shinichiro Nakamura, Koichiro Furuta, Hiroyuki Kimura, Keiji Tsuji, Yuji Kojima, Takehiro Akahane, Takashi Tamada, Yasushi Uchida, Masahiko Kondo, Akeri Mitsuda & Namiki Izumi. (2022) Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers 14:12, pages 2975.
Crossref
Shou-Wu Lee, Sheng-Shun Yang, Han-Chung Lien, Yen-Chun Peng, Chung-Wang Ko & Teng-Yu Lee. (2022) Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. Journal of Clinical Medicine 11:5, pages 1444.
Crossref
Makoto Chuma, Haruki Uojima, Nobuhiro Hattori, Yoshitaka Arase, Taito Fukushima, Shunji Hirose, Satoshi Kobayashi, Makoto Ueno, Shun Tezuka, Shuichiro Iwasaki, Naohisa Wada, Kousuke Kubota, Kota Tsuruya, Yoshimasa Shimma, Ikeda Hiroki, Ehira Takuya, Chikako Tokoro, Shigeru Iwase, Yuki Miura, Satoshi Moriya, Tsunamasa Watanabe, Hisashi Hidaka, Manabu Morimoto, Kazushi Numata, Chika Kusano, Tatehiro Kagawa & Shin Maeda. (2021) Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatology Research 52:3, pages 269-280.
Crossref
Qi Li, Mengran Cao, Guosheng Yuan, Xiao Cheng, Mengya Zang, Ming Chen, Xiaoyun Hu, Jing Huang, Rong Li, Yabing Guo, Jian Ruan & Jinzhang Chen. (2022) Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Frontiers in Oncology 12.
Crossref
. (2022) 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology 23:12, pages 1126.
Crossref
Marie Decraecker, Caroline Toulouse & Jean-Frédéric Blanc. (2021) Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers 13:24, pages 6310.
Crossref
Ilario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, Valentina Burgio, Takashi Kumada, Hideki Iwamoto, Atsushi Hiraoka, Takashi Niizeki, Masanori Atsukawa, Hironori Koga, Masashi Hirooka, Takuji Torimura, Massimo Iavarone, Raffaella Tortora, Claudia Campani, Sara Lonardi, Emiliano Tamburini, Fabio Piscaglia, Gianluca Masi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Takaaki Tanaka, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Margherita Rimini, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu & Andrea Casadei‐Gardini. (2021) Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International 41:12, pages 2997-3008.
Crossref
Morihiko Ishizaki, Masaki Kaibori, Hideyuki Matsushima, Hisashi Kosaka, Kosuke Matsui & Mitsugu Sekimoto. (2021) Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology 14:6, pages 1700-1705.
Crossref
Yuan-Hung Kuo, Sheng-Nan Lu, Yen-Yang Chen, Kwong-Ming Kee, Yi-Hao Yen, Chao-Hung Hung, Tsung-Hui Hu, Chien-Hung Chen & Jing-Houng Wang. (2021) Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology 11.
Crossref
Hirotetsu Takagi, Kosuke Kaji, Norihisa Nishimura, Koji Ishida, Hiroyuki Ogawa, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro & Hitoshi Yoshiji. (2021) The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. Cells 10:3, pages 575.
Crossref
Takeshi Hatanaka, Atsushi Naganuma & Satoru Kakizaki. (2021) Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals 14:1, pages 36.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.